Founded in 2019, S-Alpha Therapeutics develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology. Company has developed several digital therapeutic products in its R&D pipeline. Currently, company is conducting clinical trials to evaluate the efficacy, safety and feasibility of SAT-001 in several clinical sites in South Korea.